April 25, 2012 9:00 am ET
Sébastien Martel -
William J. Sibold - Head of Multiple Sclerosis Business and Senior Vice President
Michael Panzara -
Alasdair Coles -
Jeffrey Cohen -
Richard J. Parkes - Deutsche Bank AG, Research Division
Peter Verdult - Morgan Stanley, Research Division
Mark Dainty - Citigroup Inc, Research Division
Vincent Meunier - Exane BNP Paribas, Research Division
Richard Vosser - JP Morgan Chase & Co, Research Division
Philippe Lanone - Natixis Bleichroeder LLC, Research Division
Michael Leuchten - Barclays Capital, Research Division
Previous Statements by SNY
» sanofi-aventis' Management Presents at Credit Suisse Healthcare Conference (Transcript)
» Sanofi's Management Presents at Cowen Group Health Care Conference (Transcript)
» Sanofi's CEO to Present at JPMorgan Global Healthcare Conference (Transcript)
Welcome to the Sanofi Conference Call on Multiple Sclerosis. I now hand you over to Mr. Sébastien Martel, Head of Investor Relations. Sir, please go ahead.
Thank you. Hello, everyone, and welcome to our IR Thematic Call on Multiple Sclerosis. This call is made to provide you with an update on Genzyme's MS portfolio and in particular, Lemtrada. Indeed, we're here in the middle of the American Academy of Neurology meeting in New Orleans. And following the release of detailed results from CARE-MS II yesterday, we believe that it was important that we provide investors and analysts with an overview of Lemtrada's profile for CARE-MS studies.
As always, we've prepared a presentation for the call, and our slides are available to download from our website. As you know, I must advise you that the information presented on this conference call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to differ materially. Please refer to our Form 20-F on file with the SEC and also, our Document de Reference for description of these factors.
With us today on the call are Bill Sibold, Senior Vice President, Head of Multiple Sclerosis. Bill actually joined Genzyme in 2011. He is responsible for Genzyme's MS franchise as the company prepares to launch 2 products. Bill knows the MS field very well having spent a number of years at Biogen Idec in various leadership positions for MS products.
And we've got Dr. Mike Panzara, Therapeutic Area Head of Multiple Sclerosis. Mike joined Genzyme in 2009. He is, first and foremost, responsible for clinical development strategy and on oversight of the alemtuzumab program. Prior to joining Genzyme, Mike was Chief Medical Officer for neurology with Biogen Idec, where he was responsible for the development of late-stage neurology products.
We're also obviously very pleased to have 2 key opinion leaders with us on the call today. Both have tremendous experience in MS and have been involved in the CARE-MS program. Dr. Alasdair Coles from the University of Cambridge in the U.K. Dr. Coles received his degrees from the University of Oxford, London and Cambridge. He is currently a university lecturer in neuroimmunology at the University of Cambridge and an honorary Consultant Neurologist at Addenbrooke's and Peterborough hospitals. Dr. Coles has researched the effects of alemtuzumab in MS since 1994 with Professor Alastair Compston.
Dr. Jeffrey Cohen at the Cleveland Clinic. Dr. Cohen has worked with the Cleaveland Clinic's Mellen Center for MS Treatment and Research since 1994. Dr. Cohen's has the last clinical practice devoted primarily to the care of patients with MS and related disorders. In addition, he is Director of the Experimental Therapeutics Program and has been involved in various capacities in a large number of clinical trials developing new therapies for MS.
And last but not least, we also have the pleasure to have Dr. David Meeker, CEO of Genzyme with us on the call. With that, let me now turn the call over to Bill.
William J. Sibold
Thank you, Sébastien. Welcome, everyone, and good afternoon or good morning depending where you are. It's a pleasure to be here and very appropriate that we're having this call from AAN, which is the largest neurology meeting in the world. There are over 12,000 attendees at this meeting. And many of them have a interest in, obviously, in broad neurological conditions but MS is something which a lot of the attendees are very interested in.
So it's an exciting time for us to be having -- presenting such [indiscernible].
I'm going to cover a few things. I'll talk about the MS market, and it's a large market and how we are going to compete in that market. And really with the right products and approach, we believe that we cannot only compete but be leaders in the market. And finally, finish up with the progress that has been made and what we are looking forward to.
So the global MS market is significant and expected to grow. Based on actual reported company sales in 2011, the market was $12.5 billion, and this is expected to grow into 2016 and become an almost $18 billion market. This is driven by a couple of things, specifically the still high unmet need that exists and also, new entrants that will be coming in to the market.
MS itself is a very prevalent and serious disease. There are approximately 2.1 million patients worldwide, and it tends to be a disease that is prevalent in young women. In fact, it's about a 2:1 ratio, female to male prevalence. And as I said, it's a very significant serious diseases. The life expectancy is 5 to 10 years lower for people with MS. And the disease itself has a very profound impact on one's life, certainly affecting their family, social and professional lives.
Next slide. The market is still dominated by the ABCRE or the injectable products, and I'll go through those. Avonex, Betaseron, Rebif and Extavia are interferon, and they represent over 50% of the market as a class. When you put Copaxone in, which is the final ABCRE, it has over 30% share of the market. So it is actually a quite concentrated market with 5 products. Now all of these are injectables, and they are injected either daily or up to once per week, and all offer moderate efficacy. So this segment represents an opportunity for new and emerging therapies and really an opportunity for some fragmentation of that market to begin.